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Background: Human Papillomavirus (HPV) vaccination for men could prevent anal cancers amongst men who have sex with men (MSM).
Methods: An e-survey of attitudes towards vaccination for men in the UK was conducted in July–August 2014.
Results: Among 325 sexual health professionals, 14% were already vaccinating men against HPV, 83% recommended gender-
neutral HPV vaccination and 65% recommended targeting MSM. Over 50% reported having poor knowledge about the use of
HPV vaccine for MSM and the skills to identify MSM likely to benefit from HPV vaccination.
Conclusions: Clear advice and guidelines on HPV vaccine use for men at sexual health clinics are required to ensure equitable
opportunities for vaccination.
Although all men are susceptible to Human Papillomavirus (HPV)
infection, men who have sex with men (MSM) are at higher risk of
HPV-related recurrent genital warts and anal cancers (Machalek et al,
2012). The reasons for this are multifactorial including, higher
HPV-infection rates among MSM, lack of protection from
female HPV vaccination as well higher incidence of HIV infection in
MSM. HIV infection is strongly associated with persistence of HPV and
HIV-infected MSM are disproportionately affected with HPV-
associated anal cancer (Chow et al, 2014). In the UK, the Joint
Committee on Vaccination and Immunisation (JCVI) is currently
evaluating both a gender-neutral HPV vaccination, including all school-
aged boys, and targeted HPV vaccination catch-up programmes for
high-risk men such as adult MSM to reduce the HPV-related morbidity
(Joint Committee on Vaccination and Immunisation (JCVI) [England],
2014). These two strategies are not mutually exclusive and while a
gender-neutral strategy would emulate the existing school-age female
HPV vaccination programme, the feasibility and acceptability of a
targeted HPV vaccination programme for MSM is yet to be established.
Sexual health clinics have been proposed as a potential setting to
offer MSM-targeted HPV vaccination because of their existing and
related functions, such as screening for sexually transmitted
infections and provision of hepatitis vaccination to MSM. Conse-
quently, there is a need to examine the views on HPV vaccination for
MSM amongst sexual healthcare professionals (SHCPs) to measure
the potential support for an MSM-targeted HPV vaccination
programme. Unlike gender-neutral vaccination in schools, a targeted
strategy would require high acceptability rates from both MSM and
vaccination providers in order to achieve optimal uptake.
In the US, where MSM below the age of 26 years are eligible for
HPV vaccination, the strength of doctors’ recommendation is a
predictor of HPV vaccine uptake. MSM who believed their doctor
would recommend HPV vaccination were B13 times more likely to
accept it (Reiter et al, 2010). Similarly, 80% of MSM at a sexual health
clinic reported doctor’s recommendation as a reason for accepting
HPV vaccination (Thomas and Goldstone, 2011). Therefore, we
wished to explore the recommendations and attitudes towards HPV
vaccination for men among SHCPs in the UK to assess potential
acceptability and identify barriers towards HPV vaccination for MSM.
MATERIALS AND METHODS
An e-survey, containing six demographic questions and 18
attitudinal statements about the use and value of HPV vaccination
in men, was conducted during July and August 2014. Participants’
agreement with each attitudinal statement was measured using
a five-item Likert scale (‘strongly disagree’ to ‘strongly agree’).
The statements were adapted from previous studies examining
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attitudes of health professionals towards HPV vaccination
(Riedesel et al, 2005; Hopkins and Wood, 2013), and were further
modified after piloting the survey for usability and functionality.
A search of online resources and the databases of three
professional organisations (British Association of Sexual Health
and HIV, Society of Sexual Health Advisors, National HIV Nurses
Association) was undertaken to identify email addresses of
UK-based sexual health workers (i.e., consultants, nurses, health
advisors). A total of 344 addresses were identified and used to
circulate an invitation to participate in the e-survey. Recipients
were also asked to distribute the e-survey link to co-workers in
their departments. In addition, the invitation to participate was
distributed through the professional newsletters of each organisa-
tion. No incentive was offered for completion.
Descriptive statistics were used for demographic and attitudinal
data. Multiple ordinal regressions tested associations between
demographic and attitudinal variables (missing values did not
exceed 2.5% of all responses). Two-tailed Spearman’s rank tests
were used to examine the relationship between attitudinal variables
and the willingness to recommend gender-neutral or MSM-
targeted HPV vaccination strategies.
RESULTS
A total of 325 SHCPs responded (70% females, 46% doctors –
Supplementary Table A). The modal year of gaining clinical
qualification was 1993 (s.d.: 9.7). Although respondents came
mainly from the South East of England, the sample was
geographically dispersed. About 75% practised in sexual health
clinics where more than 10% of service users were MSM.
Approximately 14% of respondents reported already vaccinating
men against HPV without prior recommendations.
Although 84% agreed to recommend gender-neutral HPV
vaccination programme, regardless of sexual orientation, 65%
were supportive of MSM-targeted HPV vaccination (Table 1).
Approximately 17% expressed a lack of favour towards
MSM-targeted HPV vaccination strategy. The recommendation
of gender-neutral programme was associated with the attitude that
HPV vaccination of heterosexual men is valuable and worthwhile
(Supplementary Tables B and C). SHCPs that serve a largely
heterosexual population were more at 2.55 odds to recommend
gender-neutral HPV vaccination (CI: 1.08–6.04). The recommen-
dation of MSM-targeted HPV vaccination was associated with the
attitude that MSM would not benefit from female HPV vaccination
(r¼  0.30, Po0.002) and that targeted HPV vaccination would
encourage MSM to engage with sexual health clinics (r¼ 0.26,
Po0.002). Most respondents were unsure whether other health-
care professionals would recommend the vaccine to MSM.
When respondents were asked to indicate their views on potential
MSM-targeted HPV vaccination programmes, about 75% agreed that
MSM would accept HPV vaccine, that HPV vaccination should be
offered at no patient cost, and be available in alternative settings,
such as GP practices or pharmacists. Approximately half of the
respondents agreed that an HPV vaccination programme needs to be
available to all MSM, regardless of their age, and not subject to
assessment based on individual susceptibility. About 17% agreed that
HPV vaccination would not be effective in sexually active MSM and
5% thought that targeted HPV vaccination could lead to unsafe sex.
Interestingly, 32% reported having insufficient knowledge about the
HPV vaccination for MSM and 22% reported a lack of skills to
identify MSM potentially eligible for HPV vaccination.
SHCPs who were already vaccinating men against HPV were at
0.34 odds to disagree that MSM are not at risk of HPV-related
cancers and that MSM-targeted HPV vaccination is worthwhile
(CI: 0.20–0.70). These health professionals also perceived








I would recommend HPV vaccination of all men, regardless of their sexual orientation 271 (84%) 26 (8%) 25 (8%)
I would recommend targeting MSM to be vaccinated against HPV 207 (65%) 60 (18%) 53 (17%)
Other healthcare professionals would not recommend HPV vaccination to MSM 81 (25%) 149 (45%) 94 (30%)
Perceived population at risk
Vaccinating females against HPV will reduce HPV-related cancers in heterosexual men 271 (84%) 38 (11%) 15 (5%)
Vaccinating females against HPV will reduce HPV-related cancers in MSM 47 (15%) 66 (20%) 210 (65%)
Perceived value
HPV causes too few cancers among heterosexual men to make it worthwhile to offer vaccination 27 (8%) 66 (21%) 230 (71%)
HPV causes too few cancers among MSM to make it worthwhile to offer vaccination 7 (3%) 27 (8%) 285 (89%)
HPV causes too few cancers among HIV-positive MSM to make it worthwhile to offer vaccination 8 (3%) 22 (7%) 290 (90%)
Perceived health behaviours
The majority of MSM would be willing to receive the HPV vaccine 238 (75%) 75 (23%) 7 (2%)
HPV vaccination would encourage MSM to engage with sexual health services 190 (60%) 97 (30%) 30 (10%)
Vaccinating MSM could increase the likelihood of unsafe sex 14 (5%) 41 (13%) 266 (82%)
Perceived delivery modes
The patient should cover the vaccine cost 18 (6%) 52 (16%) 252 (78%)
Targeted HPV vaccination should be based on individual assessment of each MSM attending
sexual health clinic
85 (26%) 57 (18%) 179 (56%)
HPV vaccination should be offered to MSM in alternative settings such as GP practices or
pharmacies
239 (74%) 49 (15%) 34 (11%)
Perceived expediency
All MSM, regardless of their age, should be offered HPV vaccination 162 (51%) 80 (25%) 77 (24%)
It is too late to vaccinate against HPV if MSM are already sexually active 56 (17%) 77 (24%) 189 (59%)
Perceived capabilities
I have the skills to identify MSM that would benefit from the HPV vaccine 155 (49%) 95 (29%) 72 (22%)
I feel sufficiently informed about the HPV vaccination for MSM 143 (44%) 76 (24%) 105 (32%)
Abbreviations: HPV¼Human Papillomavirus; MSM¼men who have sex with men.
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themselves to be more knowledgeable about issues related to HPV
vaccination and MSM (OR¼ 8.49, CI: 4.05–15.1). Compared with
consultants, nurses were more likely to agree with a MSM-targeted
HPV vaccination strategy based on individual assessment
(OR¼ 3.32, CI: 1.69–5.65), despite reporting feeling uninformed
about the use of HPV vaccine specifically for MSM.
DISCUSSION
Although the majority of SHCPs support gender-neutral HPV
vaccination MSM-targeted HPV vaccination is moderately accep-
table. SHCPs perceive a need to protect MSM against HPV-related
diseases and some have already been vaccinating high-risk men,
despite a lack of policy addressing HPV prevention in MSM.
However, the age and the source of funding of vaccine recipients
were not defined. Because a fifth of respondents were against an
MSM-targeted HPV vaccination strategy, these professionals might
be less supportive of offering HPV vaccination to their MSM patients
if a catch-up programme was introduced. Moreover, more than half
of the respondents perceived a lack of adequate knowledge and skills
that would allow them to offer HPV vaccination to MSM.
Professionals that have already been vaccinating men against HPV
reported having sufficient knowledge about HPV vaccine and
positive attitudes towards a targeted HPV vaccination strategy.
Similar disparities in healthcare professionals’ opinions and concerns
about the effectiveness of various vaccination strategies have been
reported previously (Hopkins and Wood, 2013; Vadaparampil et al,
2014). Thus, in the absence of clear national guidelines on HPV
vaccination for men, such variation in attitudes and recommenda-
tions is not unexpected.
If MSM-targeted HPV vaccination is recommended in the UK,
the motivation of SHCPs will have an important role in achieving the
required uptake for an effective vaccination programme (Rosenthal
et al, 2011). The lack of active promotion of the HPV vaccine to
eligible patients, as observed in the US, could diminish uptake and
undermine the potential benefits of this strategy. Therefore, it is
essential that in parallel to a vaccination strategy there is investment
in the production of clear advice, guidelines and education to ensure
that all SHCPs offer HPV vaccination to MSM service users.
This is the first UK study to measure healthcare professionals’
attitudes towards MSM-targeted HPV vaccination, and has high-
lighted the importance of examining the motivation of health
professionals involved in vaccination delivery to monitor any impact
of attitudes and recommendation on vaccine acceptability and
uptake. The sample size is substantial and geographically diverse, but
the study lacks the perspective of other professionals likely to be
involved in targeted HPV vaccination, such as GPs or pharmacists.
Due to online recruitment methods, we do not have any assessment
of the response rate or the representativeness of the sample. There is
also a possibility of bias by self-selection. Participants’ research
knowledge was not examined. SHCPs attitudes need to be monitored
over time to ensure they remain favourable and supportive of the
current policies. Future research should identify the barriers and
enablers of potential MSM-targeted HPV vaccination and assess the
levels of HPV vaccine acceptability among MSM in the UK.
In conclusion, specific national guidelines for SHCPs on the use of
HPV vaccine for men in sexual health clinics are urgently needed to
standardise HPV vaccination practices and ensure equitable distribu-
tion of health promoting services, so that all men at high risk of HPV
are offered vaccination that reduces the risk of anal cancer.
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